This is a notable limitation, as combining adavosertib with other targeted therapies (such as KIT inhibitors) could potentially enhance efficacy or overcome resistance mechanisms in GIST, particularly in the context of TP53 mutations. Here, TP53 is linked to gastrointestinal stromal tumor.